Article
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Chinese journal of cancer - 1 Mar 2013
Suzuki Hidekazu, Hirashima Tomonori, Okamoto Norio, Yamadori Tadahiro, Tamiya Motohiro, Morishita Naoko, Shiroyama Takayuki, Otsuka Tomoyuki, Kitai Kanako, Kawase Ichiro
Abstract excerpt
For patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the relationship between the dose or duration of treatment with tyrosine kinase inhibitor (TKI) and overall survival remains unclear. Here, we analyzed clinical data of 39 patients who were diagnosed with EGFR mutation-positive non-small cell lung cancer and treated with TKI, but subsequently died. Several parameters were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.